Role of adipokines signaling in the modulation of T cells function

Frontiers in Immunology

Volumn 4, Issue , 2013, Pages

  Procaccini, Claudio ^a,b   De Rosa, Veronica ^b,c   Galgani, Mario ^b   Carbone, Fortunata ^a,b   Rocca, Claudia La ^a,b   Formisano, Luigi ^d   Matarese, Giuseppe ^a,e  

^a UNIVERSITY OF SALERNO   (Italy)

^b CNR   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^d UNIVERSITY OF SANNIO   (Italy)

^e IRCCS MULTIMEDICA   (Italy)

Author keywords

Adipocytokines; Adiponectin; Leptin; Obesity; T cells

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; COMPLEMENT FACTOR D; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RESISTIN;

ADIPOSE TISSUE; ANGIOGENESIS; APPETITE; BLOOD PRESSURE; CELLULAR IMMUNITY; DIETARY INTAKE; ENERGY BALANCE; HUMAN; IMMUNE DYSREGULATION; IMMUNE FUNCTION TEST; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INSULIN SENSITIVITY; LIFESTYLE; LIPID METABOLISM; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

EID: 84897517397     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00332     Document Type: Review

References (172)

1. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, et al. Recent advances in the relationship between obesity, inflammation, and insulin resis-tance. Eur Cytokine Netw (2006) 17:4-12.
2. Hotamisligil GS. Inflammation and metabolic disorders. Nature (2006) 14:860-7. doi:10.1038/nature05485
3. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer (2004) 4:579-91. doi:10.1038/ nrc1408
4. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a cru-cial role in the development of obesity-related insulin resistance. J Clin Invest (2003) 112:1821-30. doi:10.1172/JCI19451
5. Fantuzzi G. Adipose tis-sue, adipokines, and inflammation. J Allergy Clin Immunol (2005) 115:911-9. doi:10.1016/j.jaci.2005.02.023
6. Symonds ME, Sebert SP, Hyatt MA, Budge H. Nutritional programming of the meta-bolic syndrome. Nat Rev Endocrinol (2009) 5:604-10. doi:10.1038/nrendo.2009.195
7. Maury E, Brichard SM. Adipokine dysregulation, adipose tis-sue inflammation and meta-bolic syndrome. Mol Cell Endocrinol (2010) 314:1-16. doi:10.1016/j.mce.2009.07.031
8. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest (2005) 115:1111-9. doi:10.1172/JCI25102
9. Zhang Y, Proenca R, Maf-fei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homo-logue. Nature (1994) 372:425-32. doi:10.1038/372425a0
10. Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R, et al. Identification and expression cloning of a leptin receptor, Ob-R. Cell (1995) 83:1263-70. doi:10. 1016/0092-8674(95)90151-5
11. Montague CT, Farooqi IS, White-head JP, Soos MA, Rau H, Ware-ham NJ, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature (1997) 387:903-8. doi:10. 1038/43185
12. Krude H, Biebermann H, Luck W, Horn R, Brabant G, Grüters A. Severe early-onset obesity, adrenal insufficiency and red hair pigmen-tation caused by POMC muta-tions in humans. Nat Genet (1998) 19:155-7. doi:10.1038/509
13. Jackson RS, Creemers JW, Ohagi S, Raffin-Sanson ML, Sanders L, Montague CT, et al. Obesity and impaired pro-hormone processing associated with mutations in the human prohormone convertase 1 gene. Nat Genet (1997) 16:303-6. doi:10.1038/ng0797-303
14. Vaisse C, Clement K, Guy-Grand B, Froguel P. A frameshift muta-tion in human MC4R is associ-ated with a dominant formof obe-sity. Nat Genet (1998) 20:113-4. doi:10.1038/2407
15. Yeo GS, Farooqi IS, Aminian S, Halsall DJ, Stanhope RG,O'Rahilly S. A frameshift mutation inMC4R associated with dominantly inher-ited human obesity. Nat Genet (1998) 20:111-2. doi:10.1038/2404
16. Bochukova EG,Huang N, Keogh J, Henning E, Purmann C, Blaszczyk K, et al. Large, rare chromo-somal deletions associated with severe early-onset obesity. Nature (2010) 463:666-70. doi:10.1038/ nature08689
17. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes (1994) 43:1271-8. doi:10.2337/diabetes.43.11.1271
18. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necro-sis factor in human adipose tis-sue. Regulation by obesity, weight loss, and relationship to lipopro-tein lipase. J Clin Invest (1995) 95:2111-9. doi:10.1172/JCI117899
19. Bullo M, García-Lorda P,Megias I, Salas-Salvadó J. Systemic inflam-mation, adipose tissue tumor necrosis factor, and leptin expres-sion. Obes Res (2003) 11:525-31. doi:10.1038/oby.2003.74
20. Rasouli N, Kern PA. Adipocy-tokines and the metabolic compli-cations of obesity. JClin Endocrinol Metab (2008) 93:64-73. doi:10. 1210/jc.2008-1613
21. MacLaren R, Cui W, Cianflone K. Adipokines and the immune sys-tem: an adipocentric view. Adv Exp Med Biol (2008) 632:1-21. doi:10. 1007/978-0-387-78952-1_1
22. Dixit VD. Adipose-immune interactions during obesity and caloric restriction: recip-rocal mechanisms regulating immunity and health span. J Leukoc Biol (2008) 84:882-92. doi:10.1189/jlb.0108028
23. Bilan PJ, Samokhvalov V, Koshk-ina A, Schertzer JD, Samaan MC, Klip A. Direct and macrophage-mediated actions of fatty acids causing insulin resistance in mus-cle cells. Arch Physiol Biochem (2009) 115:176-90. doi:10.1080/ 13813450903079314
24. Bourlier V, Bouloumie A. Role of macrophage tissue infiltration in obesity and insulin resistance.Dia-betesMetab (2009) 35:251-60. doi: 10.1016/j.diabet.2009.05.001
25. Curat CA, Miranville A, Sengenes C,DiehlM, Tonus C, Busse R, et al. From blood monocytes to adipose tissue-resident macrophages: induction of diapedesis by human mature adipocytes. Diabetes (2004) 53:1285-92. doi:10.2337/diabetes.53.5.1285
26. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Fer-rante AW Jr. Obesity is associ-ated with macrophage accumu-lation in adipose tissue. J Clin Invest (2003) 112:1796-808. doi: 10.1172/JCI19246
27. Halberg N, Wernstedt-Asterholm I, Scherer PE. The adipocyte as an endocrine cell. Endocrinol Metab Clin North Am (2008) 37:753-68. doi:10.1016/j.ecl.2008.07.002
28. Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E, et al. Adipocyte death defines macrophage localization and func-tion in adipose tissue of obese mice and humans. J Lipid Res (2005) 46:2347-55. doi:10.1194/ jlr.M500294-JLR200
29. Wu H, Ghosh S, Perrard XD, Feng L, Garcia GE, Perrard JL, et al. T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. Circulation (2007) 115:1029-38. doi:10.1161/ CIRCULATIONAHA.106.638379
30. Nishimura S, Manabe I, Nagasaki M, Eto K, Yamashita H, Ohsugi M, et al. CD8+ effector T cells contribute to macrophage recruit-ment and adipose tissue inflammation in obesity. NatMed (2009) 15:914-20. doi:10.1038/nm.1964
31. Liu J, Divoux A, Sun J, Zhang J, Clément K, Glickman JN, et al. Genetic deficiency and pharmaco-logical stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat Med (2009) 15:940-5. doi:10.1038/nm.1994
32. Moro K, Yamada T, Tan-abe M, Takeuchi T, Ikawa T, Kawamoto H, et al. Innate pro-duction of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature (2009) 463:540-4. doi:10.1038/nature08636
33. Lumeng CN, Maillard I, Saltiel AR. T-ing up inflammation in fat. Nat Med (2009) 15:846-7. doi:10. 1038/nm0809-846
34. Feuerer M, Herrero L, Cipolletta D, Naaz A, Wong J, Nayer A, et al. Lean, but not obese, fat is enriched for a unique population of reg-ulatory T cells that affect meta-bolic parameters. Nat Med (2009) 15:930-9. doi:10.1038/nm.2002
35. Winer S, Chan Y, Paltser G, Truong D, Tsui H, Bahrami J, et al. Nor-malization of obesity-associated insulin resistance through immunotherapy. Nat Med (2009) 15:921-9. doi:10.1038/nm.2001
36. Friedman JM, Halaas JL. Lep-tin and the regulation of body weight inmammals.Nature (1998) 395:763-70. doi:10.1038/27376
37. Zhang F, Basinski MB, Beals JM, Briggs SL, Churgay LM, Claw-son DK, et al. Crystal structure of the obese protein leptin-E100. Nature (1997) 387:206-9. doi:10. 1038/387206a0
38. HouseknechtKL,BaileCA,Matteri RL, Spurlock ME. The biology of leptin: a review. J Anim Sci (1998) 76:1405-20.
39. La Cava A,Matarese G. The weight of leptin in immunity. Nat Rev Immunol (2004) 4:371-9. doi:10. 1038/nri1350
40. Matarese G, La Cava A, Sanna V, Lord GM, Lechler RI, Fontana S, et al. Balancing susceptibil-ity to infection and autoimmu-nity: a role for leptin? Trends Immunol (2002) 23:182-7. doi:10. 1016/S1471-4906(02)02188-9
41. Chehab F, Lim M, Lu R. Cor-rection of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nat Genet (1996) 12:318-20. doi:10.1038/ng0396-318
42. Bennett BD, Solar GP, Yuan JQ, Mathias J, Thomas GR, Matthews W. A role for lep-tin and its cognate receptor in hematopoiesis. Curr Biol (1996) 6: 1170-80. doi:10.1016/S0960-9822(02)70684-2
43. Sierra-Honigmann MR, Nath AK, Murakami C, García-Cardeña G, Papapetropoulos A, Sessa WC, et al. Biological action of leptin as an angiogenic factor. Science (1998) 281:1683-6. doi:10.1126/ science.281.5383.1683
44. Park HY, Kwon HM, Lim HJ, Hong BK, Lee JY, Park BE, et al. Potential role of leptin in angio-genesis: leptin induces endothe-lial cell proliferation and expres-sion of matrix metalloproteinases in vivo and in vitro. Exp Mol Med (2001) 33:95-102. doi:10. 1038/emm.2001.17
45. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, et al. Leptin inhibits bone formation through a hypothal-amic relay: a central control of bone mass. Cell (2000) 100: 197-207. doi:10.1016/S0092-8674(00)81558-5
46. Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI. Leptin modulates the T-cell immune response and reverses starvation-induced immuno-suppression. Nature (1998) 394:897-901. doi:10.1038/29795
47. Sanchez-Margalet V, Martín-Romero C, Santos-Alvarez J, Goberna R, Najib S, Gonzalez-Yanes C. Role of leptin as an immunomodulator of blood mononuclear cells:mechanisms of action. Clin Exp Immunol (2003) 133:11-9. doi:10.1046/j.1365-2249.2003.02190.x
48. Procaccini C, Jirillo E,Matarese G. Leptin as an immunomodulator. Mol Aspects Med (2012) 33:35-45. doi:10.1016/j.mam.2011.10.012
49. Gorska E, Popko K, Stelmaszczyk-EmmelA,CiepielaO,KucharskaA, Wasik M. Leptin receptors. Eur J Med Res (2010) 15:50-4.
50. Ghilardi N, Skoda RC. The lep-tin receptor activates Janus kinase 2 and signals for proliferation in a factor-dependent cell line. Mol Endocrinol (1997) 11:393-9. doi: 10.1210/me.11.4.393
51. White DW, Wang DW, Chua SC Jr,Morgenstern JP, Leibel RL, Bau-mann H, et al. Constitutive and impaired signaling of leptin recep-tors containing the Gln → Pro extracellular domain fatty muta-tion. Proc Natl Acad Sci U S A (1997) 94:10657-62. doi:10.1073/ pnas.94.20.10657
52. Chua SC, Koutras IK, Han L, Liu SM, Kay J, Young SJ, et al. Fine structure of the murine lep-tin receptor gene: splice site sup-pression is required to form two alternatively spliced transcripts. Genomics (1997) 45:264-70. doi: 10.1006/geno.1997.4962
53. Kloek C, Haq AK, Dunn SL, Lavery HJ, Banks AS,Myers MG. Regulation of Jak kinases by intracel-lular leptin receptor sequences. J Biol Chem (2002) 277:41547-55. doi:10.1074/jbc.M205148200
54. Jiang N, He TC, Miyajima A,Wojchowski DM. The box1 domain of the erythropoietin receptor specifies Janus kinase 2 activa-tion and functions mitogenically within an interleukin 2 beta-receptor chimera. J Biol Chem (1996) 271:16472-6. doi:10.1074/ jbc.271.28.16472
55. Murakami M, Narazaki M, Hibi M, Yawata H, Yasukawa K, Hamaguchi M, et al. Critical cytoplas-mic region of the interleukin 6 signal transducer gp130 is con-served in the cytokine receptor family. Proc Natl Acad Sci U S A (1991) 88:11349-53. doi:10.1073/ pnas.88.24.11349
56. Bahrenberg G, Behrmann I, Barthel A, Hekerman P, Heinrich PC, Joost HG, et al. Identification of the critical sequence elements in the cytoplasmic domain of leptin receptor isoforms required for Janus kinase/signal transducer and activator of transcription activation by receptor het-erodimers. Mol Endocrinol (2002) 16:859-72. doi:10.1210/me.16.4. 859
57. Banks AS, Davis SM, Bates SH, Myers MG. Activation of down-stream signals by the long form of the leptin receptor. J Biol Chem (2000) 275:14563-72. doi: 10.1074/jbc.275.19.14563
58. Eyckerman S, Waelput W, Verhee A, Broekaert D, Vandekerckhove J, Tavernier J, et al. Analysis of Tyr to Phe and fa/fa leptin recep-tor mutations in the PC12 cell line. Eur Cytokine Netw (1999) 10:549-56.
59. Baumann H, Morella KK, White DW, Dembski M, Bailon PS, Kim H, et al. The full-length leptin receptor has signaling capabili-ties of interleukin 6-type cytokine receptors. Proc Natl Acad Sci U S A (1996) 93:8374-8. doi:10.1073/ pnas.93.16.8374
60. Bendinelli P, Maroni P, Pecori Giraldi F, Piccoletti R. Leptin activates Stat3, Stat1 and AP-1 in mouse adipose tissue. Mol Cell Endocrinol (2000) 168:11-20. doi:10.1016/S0303-7207(00) 00313-0
61. Bates SH, Stearns WH, Dun-don TA, Schubert M, Tso AW, Wang Y, et al. STAT3 signalling is required for leptin regulation of energy balance but not repro-duction.Nature (2003) 421:856-9. doi:10.1038/nature01388
62. Cui Y, Huang L, Elefteriou F, Yang G, Shelton JM, Giles JE, et al. Essential role of STAT3 in body weight and glucose homeostasis. Mol Cell Biol (2004) 24:258-69. doi:10.1128/MCB.24.1.258-269. 2004
63. Gao Q, Wolfgang MJ, Neschen S, Morino K, Horvath TL, Shulman GI, et al. Disruption of neural sig-nal transducer and activator of transcription 3 causes obesity, dia-betes, infertility, and thermal dys-regulation. Proc Natl Acad Sci U S A (2004) 101:4661-6. doi:10.1073/ pnas.0303992101
64. Gong Y, Ishida-Takahashi R, Vil-lanueva EC, Fingar DC,Munzberg H, Myers MG Jr. The long form of the leptin receptor regulates STAT5 and ribosomal protein S6 via alternate mechanisms. J Biol Chem (2007) 282:31019-27. doi: 10.1074/jbc.M702838200
65. Mutze J, Roth J, Gerstberger R, Hubschle T. Nuclear translocation of the transcription factor STAT5 in the rat brain after systemic lep-tin administration. Neurosci Lett (2007) 417:286-91. doi:10.1016/j. neulet.2007.02.074
66. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, et al. A family of cytokine-inducible inhibitors of signalling. Nature (1997) 387:917-21. doi:10. 1038/43206
67. Sahu A. Leptin signaling in the hypothalamus: emphasis on energy homeostasis and leptin resistance. Front Neuroendocrinol (2004) 24:225-53. doi:10.1016/j. yfrne.2003.10.001
68. Bjørbæck C, Elmquist JK, Frantz JD, Shoelson SE, Flier JS. Identification of SOCS-3 as a potential mediator of central leptin resis-tance. Mol Cell (1998) 1:619-25. doi:10.1016/S1097-2765(00) 80062-3
69. Bjørbæck C, El Haschimi K, Frantz JD, Flier JS. The role of SOCS-3 in leptin signaling and leptin resistance. J Biol Chem (1999) 274:30059-65. doi: 10.1074/jbc.274.42.30059
70. Bjørbæck C, Lavery HJ, Bates SH, Olson RK, Davis SM, Flier JS, et al. SOCS3 mediates feed-back inhibition of the leptin receptor via Tyr985. J Biol Chem (2000) 275:40649-57. doi:10.1074/jbc.M007577200
71. Münzberg H, Myers MG. Molec-ular and anatomical determinants of central leptin resistance. Nat Neurosci (2005) 5:566-70. doi:10. 1038/nn1454
72. Zhang EE, Chapeau E, Hag-ihara K, Feng GS. Neuronal Shp2 tyrosine phosphatase con-trols energy balance and metab-olism. Proc Natl Acad Sci U S A (2004) 101:16064-8. doi:10.1073/ pnas.0405041101
73. Li C, Friedman JM. Leptin recep-tor activation of SH2 domain containing protein tyrosine phos-phatase 2 modulates Ob recep-tor signal transduction. Proc Natl Acad Sci U S A (1999) 96: 9677-81. doi:10.1073/pnas.96.17. 9677
74. Bjorbaek C, Buchholz RM, Davis SM, Bates SH, Pierroz DD, Gu H, et al. Divergent roles of SHP-2 in ERK activation by leptin receptors. J Biol Chem (2001) 276:4747-55. doi:10.1074/jbc.M007439200
75. Sweeney G. Leptin signalling. Cell Signal (2002) 14:655-63. doi:10. 1016/S0898-6568(02)00006-2
76. Vanhaesebroeck B,WaterfieldMD. Signaling by distinct classes of phosphoinositide 3-kinases. Exp CellRes (1999) 253:239-54. doi:10. 1006/excr.1999.4701
77. Kim MS, Pak YK, Jang PG, Namkoong C, Choi YS, Won JC, et al. Role of hypothalamic Foxo1 in the regulation of food intake and energy homeostasis. Nat Neu-rosci (2006) 9:901-6. doi:10.1038/ nn1731
78. Kitamura T, Feng Y, Kitamura YI, Chua SC Jr, Xu AW, Barsh GS, et al. Forkhead protein FoxO1 mediatesAgrp-dependent effects of leptin on food intake.NatMed (2006) 12:534-40. doi:10.1038/nm1392
79. Matsuzaki H, Daitoku H, Hatta M, Tanaka K, Fukamizu A. Insulininduced phosphorylation of FKHR(Foxo1) targets to proteasomal degradation. Proc Natl Acad Sci U S A (2003) 100:11285-90. doi:10.1073/pnas.1934283100
80. Tang ED, Nunez G, Barr FG, Guan KL. Negative regulation of the forkhead transcription factor FKHR by Akt. J Biol Chem (1999) 274:16741-6. doi:10.1074/jbc.274. 24.16741
81. Cota D, Proulx K, Smith KA, Kozma SC, Thomas G,Woods SC, et al. Hypothalamic mTOR sig-naling regulates food intake. Sci-ence (2006) 312:927-30. doi:10. 1126/science.1124147
82. Blouet C, Ono H, Schwartz GJ. Mediobasal hypothalamic p70 S6 kinase 1 modulates the control of energy homeostasis. Cell Metab (2008) 8:459-67. doi:10.1016/j. cmet.2008.10.004
83. Rui L. A link between protein translation and body weight. J Clin Invest (2007) 117:310-3. doi:10. 1172/JCI31289
84. Gao X, Zhang Y, Arrazola P, Hino O,Kobayashi T,Yeung RS, et al. Tsc tumour suppressor proteins antag-onize amino-acid-TOR signalling. Nat Cell Biol (2002) 4:699-704. doi:10.1038/ncb847
85. InokiK,LiY,ZhuT,Wu J,GuanKL. TSC2 is phosphorylated and inhib-ited by Akt and suppresses mTOR signalling. Nat Cell Biol (2002) 4:648-57. doi:10.1038/ncb839
86. Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Ble-nis J. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A (2002) 99:13571-6. doi:10.1073/ pnas.202476899
87. Loffreda S, Yang SQ, Lin HZ, Karp CL, Brengman ML, Wang DJ, et al. Leptin regulates proinflamma-tory immune responses. FASEB J (1998) 12:57-65.
88. Martín-Romero C, Santos-Alvarez J, Goberna R, Sánchez-Margalet V. Human leptin enhances activa-tion and proliferation of human circulating T lymphocytes. Cell Immunol (2000) 199:15-24. doi: 10.1006/cimm.1999.1594
89. Sanchez-Margalet V, Martin-Romero C. Human leptin sig-naling in human peripheral blood mononuclear cells: activa-tion of the JAK-STAT pathway. Cell Immunol (2001) 211:30-6. doi:10.1006/cimm.2001.1815
90. Vaisse C, Halaas JL, Horvath CM, Darnell JE, Stoffel M, Friedman JM. Leptin activation of STAT3 in the hypothalamus of wild-type and ob/ob mice but not db/db mice. Nat Genet (1996) 14:95-7. doi:10.1038/ng0996-95
91. Schwartz MW, Seeley RJ, Camp-field LA, Burn P, Baskin DG. Identification of targets of leptin action in rat hypothalamus. J Clin Invest (1996) 98:1101-6. doi:10. 1172/JCI118891
92. Fumagalli S, Totti N, Hsuan JJ, Coutneidge SA. A target of Src in mitosis. Nature (1994) 368:871-4. doi:10.1038/368871a0
93. Fusaki N, Iwamatsu A, Iwashima M, Fujisawa JI. Interaction between Sam68 and src family tyrosine kinases Fyn and Lck, in T cell receptor signalling. J Biol Chem (1995) 272:6214-9.
94. Jabado N, Pallier A, LeDeist F, Bernard F, Fischer A, Hivroz C. CD4 ligands inhibit the forma-tion of multifunctional transduc-tion complexes involved in T cell activation. J Immunol (1997) 158:94-103.
95. Jabado N, Jauliac S, Pallier A, Bernard F, Fischer A, Hivroz C. Sam68 association with p120GAP in CD4+ T cells is dependent on CD4 molecule expression. J Immunol (1998) 161:2798-803.
96. Sánchez-Margalet V, Najib S. Sam68 is a substrate of the insulin receptor and associates with the SH2 domains of p85 PI3K. FEBS Lett (1999) 455:307-10. doi:10. 1016/S0014-5793(99)00887-X
97. Sung CK, Sanchez-Margalet V, Goldfine ID. Role of p85 subunits of phosphatidylinositol-3-kinase as an adaptor molecule linking the insulin receptor, p62 and GTPase-activating protein. J Biol Chem (1994) 269:12503-7.
98. Martín-Romero C, Sanchez-Margalet V. Human leptin activates PI3K and MAPK path-ways in human peripheral blood mononuclear cells. Possible role of Sam68. Cell Immunol (2001) 212: 83-91. doi:10.1006/cimm.2001.1851.
99. Mansour E, Pereira FG, Araújo EP, Amaral ME, Morari J, Ferraroni NR, et al. Leptin inhibits apoptosis in thymus through a Janus kinase-2-independent, insulin receptor substrate-1/phosphatidylinositol-3 kinase-dependent pathway. Endocrinology (2006) 147:5470-9. doi:10.1210/en.2006-0223.
100. Gressner AM,Wool IG. The phos-phorylation of liver ribosomal pro-teins in vivo. Evidence that only a single small subunit is phos-phorylated. J Biol Chem (1974) 249:6917-25.
101. Takahashi Y, Okimura Y, Mizuno I, Iida K, Takahashi T, Kaji H, et al. Leptin induces mitogen-activated protein kinase-dependent prolifer-ation of C3H10T1/2 cells. J Biol Chem (1997) 272:12897-900. doi: 10.1074/jbc.272.20.12897.
102. Tanabe K, Okuya S, Tanizawa Y, Matsutani A, Oka Y. Leptin induces proliferation of pancre-atic ß cell line MIN6 through acti-vation of mitogen-activated pro-tein kinase. Biochem Biophys Res Commun (1997) 241:765-8. doi: 10.1006/bbrc.1997.7894.
103. Bouloumié A, Marumo T, Lafontan M, Busse R. Leptin induces oxidative stress in human endothelial cells. FASEB J (1999) 13:1231-8.
104. Burnett PE, Barrow RK, Cohen NA, Snyder SH, Sabatini DM. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad SciUSA (1998) 95:1432-6. doi:10. 1073/pnas.95.4.1432.
105. Lenormand P, Brondello JM, Brunet A, Pouyssegur J. Growth factor-induced p42/p44 MAPK nuclear translocation and reten-tion requires both MAPK activa-tion and neosynthesis of nuclear anchoring proteins. J Cell Biol (1998) 142:625-33. doi:10.1083/ jcb.142.3.625.
106. Eguchi S, Iwasaki H, Ueno H, Frank GD, Motley ED, Eguchi K, et al. Intracellular signal-ing of angiotensin II-induced p70 S6 kinase phosphorylation at Ser(411) in vascular smooth muscle cells. Possible require-ment of epidermal growth factor receptor, Ras, extracellular signal-regulated kinase, and Akt. J Biol Chem (1999) 274:36843-51. doi: 10.1074/jbc.274.52.36843.
107. De Rosa V, Procaccini C, Calí G, Pirozzi G, Fontana S, Zap-pacosta S, et al. A key role of leptin in the control of regula-tory T cell proliferation. Immunity (2007) 26:241-55. doi:10.1016/j. immuni.2007.01.011
108. Procaccini C, De Rosa V, Gal-gani M, Carbone F, Cassano S, Greco D, et al. Leptin-induced mTOR activation defines a spe-cificmolecular and transcriptional signature controlling CD4+ effec-tor T cell responses. J Immunol (2012) 189:2941-53. doi:10.4049/jimmunol.1200935
109. Galgani M, Procaccini C, De Rosa V, Carbone F, Chieffi P, La Cava A, et al. Leptin modulates the survival of autoreactive CD4+ T cells through the nutrient/energy-sensing mammalian target of rapamycin signaling pathway. J Immunol (2010) 185:7474-9. doi: 10.4049/jimmunol.1001674
110. Procaccini C, De Rosa V, Galgani M,Abanni L,CalíG,PorcelliniA, et al. An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness. Immunity (2010) 33:929-41. doi:10.1016/j.immuni. 2010.11.024
111. Procaccini C, Galgani M, De Rosa V, Matarese G. Intracel-lular metabolic pathways con-trol immune tolerance. Trends Immunol (2012) 33:1-7. doi:10. 1016/j.it.2011.09.002
112. Wong GW, Wang J, Hug C, Tsao TS, Lodish HF. A family of Acrp30/adiponectin structural and functional paralogs. ProcNatlAcad Sci U S A (2004) 101:10302-7. doi:10.1073/pnas.0403760101
113. Stofkova A. Leptin and adiponectin: from energy and metabolic dysbalance to inflammation and autoimmunity. Endocr Regul (2009) 43:157-68.
114. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med (2002) 8:731-7. doi:10.1038/nm724
115. Fasshauer M, Kralisch S, Klier M, Lossner U, Bluher M, Klein J, et al. Adiponectin gene expres-sion and secretion is inhib-ited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun (2003) 301:1045-50. doi: 10.1016/S0006-291X(03)00090-1
116. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev (2005) 26:439-51. doi:10.1210/er.2005-0005
117. Pang TT, Narendran P. The distri-bution of adiponectin receptors on human peripheral bloodmononu-clear cells. Ann N Y Acad Sci (2008) 1150:143-5. doi:10.1196/ annals.1447.021
118. Snehalatha C, Mukesh B, Simon M, Viswanathan V, Haffner SM, Ramachandran A. Plasma adiponectin is an indepen-dent predictor of type 2 dia-betes in Asian Indians. Dia-betes Care (2003) 26:3226-9. doi:10.2337/diacare.26.12.3226
119. Wang AYH, Hickman IJ, Richards AA, Whitehead JP, Prins JB, MacDonald GA. High molec-ular weight adiponectin corre-lates with insulin sensitivity in patients with hepatitis C geno-type 3, but not genotype 1 infec-tion. Am J Gastroenterol (2005) 100:2717-23. doi:10.1111/j.1572-0241.2005.00311.x
120. Mao X, Kikani CK, Riojas RA, Langlais P,Wang L, Ramos FJ, et al. APPL1 binds to adiponectin recep-tors and mediates adiponectin sig-nalling and function. Nat Cell Biol (2006) 8:516-23. doi:10.1038/ ncb1404
121. Cheng KK, Lam KS, Wang Y, Huang Y, Carling D, Wu D, et al. Adiponectin-induced endothe-lial nitric oxide synthase activation and nitric oxide production are mediated by APPL1 in endothelial cells. Diabetes (2007) 56:1387-94. doi:10.2337/db06-1580
122. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation (1999) 100:2473-6. doi:10.1161/01.CIR. 100.25.2473
123. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively reg-ulates the growth of myelomono-cytic progenitors and the functions of macrophages. Blood (2000) 96:1723-32.
124. Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Com-mun (2004) 323:630-5. doi:10.1016/j.bbrc.2004.08.145
125. Yamaguchi N, Argueta JG, Masuhiro Y, Kagishita M, Nonaka K, Saito T, et al. Adiponectin inhibits toll-like receptor family-induced signaling. FEBS Lett (2005) 579:6821-6. doi:10.1016/j.febslet.2005.11.019
126. Kim KY, Kim JK, Han SH, Lim JS, Kim KI, Cho DH, et al. Adiponectin is a negative regulator of NK cell cytotoxicity. J Immunol (2006) 176:5958-64.
127. Shoji T, Shinohara K, Hatsuda S, Kimoto E, Fukumoto S, Emoto M, et al. Altered relationship between body fat and plasma adiponectin in end-stage renal disease.Metabo-lism (2005) 54:330-4. doi:10.1016/ j.metabol.2004.09.012
128. D'Anna R, Baviera G, Corrado F, Giordano D, De Vivo A, Nic-ocia G, et al. Adiponectin and insulin resistance in early-and late-onset pre-eclampsia. BJOG (2006) 113:1264-9. doi:10.1111/j. 1471-0528.2006.01078.x
129. Otero M, Lago R, Gomez R, Lago F, Dieguez C, Gomez-Reino JJ, et al. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheuma-toid arthritis. Ann Rheum Dis (2006) 65:1198-201. doi:10.1136/ ard.2005.046540
130. Haugen F, Drevon CA. Activa-tion of nuclear factor-kappaB by high molecular weight and glob-ular adiponectin. Endocrinology (2007) 148:5478-86. doi:10.1210/ en.2007-0370
131. Hattori Y, Hattori S, Kasai K. Globular adiponectin activates nuclear factor-kappa B in vas-cular endothelial cells, which in turn induces expression of proinflammatory and adhesion molecule genes. Diabetes Care (2006) 29:139-41. doi:10.2337/ diacare.29.01.06.dc05-1364
132. Hattori Y, Nakano Y, Hat-tori S, Tomizawa A, Inukai K, Kasai K. High molecular weight adiponectin activates AMPK and suppresses cytokine-induced NF-kappa B activa-tion in vascular endothelial cells. FEBS Lett (2008) 582: 1719-24. doi:10.1016/j.febslet. 2008.04.037
133. Liao WQ, Yu CA, Wen JY, Jia W, Li G, Ke YA, et al. Adiponectin induces interleukin-6 production and activates STAT3 in adult mouse cardiac fibroblasts. Circulation (2010) 122:E193-193. doi:10.1042/BC20080117
134. Wang Y, Lam KSL, Xu JY, Lu G, Xu LY, Cooper GJS, et al. Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem (2005) 280:18341-7. doi:10.1074/jbc.M501149200
135. Palanivel R, Fang XP, Park M, Eguchi M, Pallan S, De Giro-lamo S, et al. Globular and full-length forms of adiponectinmedi-ate specific changes in glucose and fatty acid uptake and metabolism in cardiomyocytes. Cardiovasc Res (2007) 75:148-57. doi:10.1016/j. cardiores.2007.04.011
136. Wilk S, Scheibenbogen C, Bauer S, Jenke A, Rother M, Guerreiro M, et al. Adiponectin is a negative reg-ulator of antigen-activated T cells. Eur J Immunol (2011) 41:2323-32. doi:10.1002/eji.201041349
137. Okamoto Y, Christen T, Shimizu K, Asano K, Kihara S, Mitchell RN, et al. Adiponectin inhibits allograft rejection in murine car-diac transplantation. Transplan-tation (2009) 88:879-83. doi:10. 1097/TP.0b013e3181b6efbf
138. Tsang JY, Li D, Ho D, Peng J, Xu A, Lamb J, et al. Novel immunomodulatory effects of adiponectin on dendritic cell functions. Int Immunophar-macol (2011) 11:604-9. doi:10.1016/j.intimp.2010.11.009
139. Okamoto Y, Folco EJ, Minami M, Wara AK, Feinberg MW, Sukhova GK, et al. Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruit-ment in atherogenesis. Circ Res (2008) 102:218-25. doi:10.1161/ CIRCRESAHA.107.164988
140. Cheng X, Folco EJ, Shimizu K, Libby P. Adiponectin induces pro-inflammatory programs in human macrophages and CD4+ T cells. J Biol Chem (2012) 287:36896-904. doi:10.1074/jbc.M112.409516
141. Jung MY, Kim HS, Hong HJ, Youn BS, Kim TS. Adiponectin induces dendritic cell activation via PLCγ/JNK/NF-κB pathways, lead-ing to Th1 and Th17 polarization. J Immunol (2012) 188:2592-601. doi:10.4049/jimmunol.1102588
142. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature (2001) 409:307-12. doi:10.1038/ 35053000
143. Holcomb IN, Kabakoff RC, Chan B, Baker TW, Gurney A, Hen-zel W, et al. FIZZ1, a novel cysteine-rich secreted protein asso-ciated with pulmonary inflamma-tion, defines a new gene family. EMBO J (2000) 19:4046-55. doi: 10.1093/emboj/19.15.4046
144. Patel SD, Rajala MW, Rossetti L, Scherer PE, Shapiro L. Disulfidedependentmultimeric assembly of resistin family hormones. Science (2004) 304:1154-8. doi:10.1126/ science.1093466
145. Rea R, Donnelly R. Resistin: an adipocyte-derived hormone. Has it a role in diabetes and obesity? Diabetes Obes Metab (2004) 6:163-70. doi:10.1111/j.1462-8902.2004.00334.x
146. Kusminski CM, McTernan PG, Kumar S. Role of resistin in obesity, insulin resistance and Type II diabetes. Clin Sci (Lond) (2005) 109:243-56. doi:10.1042/CS20050078
147. Kaser S, Kaser A, Sandhofer A, Ebenbichler CF, Tilg H, Patsch JR. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun (2003) 309:286-90. doi:10.1016/j.bbrc.2003.07.003
148. Harsch IA, Koebnick C, Wal-laschofski H, Schahin SP, Hahn EG, Ficker JH, et al. Resistin levels in patients with obstructive sleep apnoea syndrome -the link to subclinical inflammation? Med Sci Monit (2004) 10:CR510-5.
149. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation (2005) 111:932-9. doi:10.1161/01.CIR. 0000155620.10387.43
150. Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med (2004) 1:45. doi:10. 1371/journal.pmed.0010045
151. Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD, et al. Resistin promotes endothe-lial cell activation: further evidence of adipokine-endothelial interaction. Circulation (2003) 108:736-40. doi:10.1161/01.CIR. 0000084503.91330.49
152. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory prop-erties. J Immunol (2005) 174: 5789-95.
153. Son YM, Ahn SM, Kim GR, Moon YS,KimSH,ParkYM, et al.Resistin enhances the expansion of regu-latory T cells through modulation of dendritic cells. BMC Immunol (2010) 11:33. doi:10.1186/1471-2172-11-33
154. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science (2005) 307:426-30. doi:10.1126/science.1097243
155. Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD, et al. Pre-B cell colony-enhancing fac-tor inhibits neutrophil apopto-sis in experimental inflammation and clinical sepsis. J Clin Invest (2004) 113:1318-27. doi:10.1172/ JCI200419930
156. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol (1994) 14:1431-7.
157. Ye SQ, Simon BA, Maloney JP, Zambelli-Weiner A, Gao L, Grant A, et al. Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury. Am J Respir Crit Care Med (2005) 171:361-70. doi:10.1164/ rccm.200404-563OC
158. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, et al. Visfatin, an adipocytokine with proinflam-matory and immunomodulating properties. J Immunol (2007) 178: 1748-58.
159. Lebedeva T, Dustin ML, Sykulev Y. ICAM-1 co-stimulates target cells to facilitate antigen presenta-tion. Curr Opin Immunol (2005) 17:251-8. doi:10.1016/j.coi.2005.04.008
160. White RT, Damm D, Hancock N, Rosen BS, Lowell BB,Usher P, et al. Human adipsin is identical to com-plement factor D and is expressed at high levels in adipose tissue. J Biol Chem (1992) 267:9210-3.
161. Gabrielsson BG, Johansson JM, Lonn M, Jernas M, Olbers T, Pel-tonen M, et al. High expression of complement components in omental adipose tissue in obese men. Obes Res (2003) 11:699-708. doi:10.1038/oby.2003.100
162. Cianflone K, Xia Z, Chen LY. Criti-cal review of acylation-stimulating protein physiology in humans and rodents. Biochim Biophys Acta (2003) 1609:127-43. doi:10.1016/ S0005-2736(02)00686-7
163. Powell JD, Delgoffe GM. The mammalian target of rapamycin: linking T cell differentiation, func-tion, and metabolism. Immunity (2010) 33:301-11. doi:10.1016/j.immuni.2010.09.002
164. Peter C, Waldmann H, Cobbold SP. mTOR signalling and meta-bolic regulation of T cell dif-ferentiation. Curr Opin Immunol (2010) 5:655-61. doi:10.1016/j.coi.2010.08.010
165. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell (2002) 110:163-75. doi:10.1016/ S0092-8674(02)00808-5
166. Sarbassov DD, Ali SM, Kim DH, GuertinDA, Latek RR, Erdjument-Bromage H, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol (2004) 14:1296-302. doi: 10.1016/j.cub.2004.06.054
167. Delgoffe GM, Pollizzi KN, Waick-man AT, Heikamp E, Meyers DJ, Horton MR, et al. The kinase mTOR regulates the differentia-tion of helper T cells through the selective activation of signal-ing by mTORC1 and mTORC2. Nat Immunol (2011) 12:295-303. doi:10.1038/ni.2005
168. Lee K, Gudapati P, Dragovic S, Spencer C, Joyce S, Killeen N, et al. Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity (2010) 32: 743-53. doi:10.1016/j.immuni. 2010.06.002
169. Sauer S, Bruno L,Hertweck A, Fin-lay D, Leleu M, Spivakov M, et al. T cell receptor signaling con-trols Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci U S A (2008) 105:7797-802. doi:10.1073/pnas.0800928105
170. Haxhinasto S, Mathis D, Benoist C. The AKT-mTOR axis regu-lates de novo differentiation of CD4+Foxp3+ cells. J Exp Med (2008) 205:565-74. doi:10.1084/ jem.20071477
171. Delgoffe GM, Kole TP, Zheng Y, Zarek PE, Matthews KL, Xiao B, et al. The mTOR kinase dif-ferentially regulates effector and regulatory T cell lineage com-mitment. Immunity (2009) 30: 832-44. doi:10.1016/j.immuni. 2009.04.014
172. Cipolletta D, Feuerer M, Li A, Kamei N, Lee J, Shoelson SE, et al. PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature (2012) 486:549-53. doi:10.1038/ nature11132